Q3 2025 Indutrade AB Earnings Call Transcript
Key Points
- Order intake improved by 3% organically, marking the best level since Q4 2023.
- Strong performance in the medical technology and pharmaceuticals sectors, contributing to overall demand.
- Successful acquisition strategy with 10 companies acquired in 2025, enhancing growth potential.
- EBITDA margin remained robust at 14.6%, despite a slight decrease from the previous year.
- Operational cash flow remained strong, with a high cash conversion rate of 133% on a rolling four-quarter basis.
- Net sales decreased by 2% due to currency headwinds, divestments, and a 1% organic decline.
- Sales in Denmark and North America faced challenges due to strong prior-year comparisons and tariff-related hesitations.
- EBITDA decreased by 3% year-over-year, impacted by lower organic sales and higher organic expenses.
- Market uncertainty remains, with a slightly lower order book and challenging references affecting organic sales.
- Earnings per share decreased by 4% in the quarter, influenced by higher tax costs and lower operational results.
Welcome to the Indutrade Q3 presentation for 2025. (Operator Instructions) Now I will hand the conference over to CEO, Bo Annvik; and CFO, Patrik Johnson. Please go ahead.
Welcome and good morning on our behalf as well. As usual, let's start with the overall highlights of the report. In terms of the demand situation, the order intake improved versus last year. 4 out of 5 business areas and more than half of the companies grew organically.
Demand from customers within medical technology and pharmaceuticals was strong, and we also saw improvements in several of the larger customer segments. Net sales decreased 2% in total organically minus 1%. The EBITDA margin came in strong at 14.6%. Our companies were also successful in terms of working capital efficiency and the inventory reductions continued during the quarter.
We had a very successful quarter in terms of acquisitions, welcoming 6 companies during the quarter.
10 acquisitions completed so far in 2025
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
